Diethylene glycol monoethyl ether: An emerging solvent in topical dermatology products

Journal of Cosmetic Dermatology

Volumn 10, Issue 4, 2011, Pages 324-329

  Osborne, David W ^a  

^a TOLMAR Inc   (United States)

Author keywords

Acne; Barrier function; Drug delivery formulation; Topical administration

Indexed keywords

COSMETIC; DAPSONE; DIETHYLENE GLYCOL MONOETHYL ETHER; SOLVENT;

ACNE; ARTICLE; DRUG FORMULATION; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; SKIN CARE; SKIN FLORA; SKIN PERMEABILITY; STRATUM CORNEUM;

ACNE VULGARIS; ANTI-INFECTIVE AGENTS; COSMETICS; DAPSONE; ETHYLENE GLYCOLS; HUMANS; SKIN; SKIN ABSORPTION; SOLVENTS;

EID: 83255170475     PISSN: 14732130     EISSN: 14732165     Source Type: Journal    
DOI: 10.1111/j.1473-2165.2011.00590.x     Document Type: Article

References (30)

1. Lipid Excipients for Topical Drug Delivery. Available at: [Accessed on August 24, 2011].
2. USP-NF National Formulary 29th edition monograph entitled Diethylene Glycol Monoethyl Ether. Official beginning May 1, 2011. United States Pharmacopeial Convention, Rockville, MD.
3. EWG's Skin Deep Cosmetics Database. Available at: [Accessed on July 13, 2011].
4. Scientific Committee on Consumer Products (SCCP), 2006, Opinion on diethylene glycol monoethyl ether (DEGEE). Available at: [Accessed on July 13, 2011].
5. Aczone [package insert]. Irvine, CA: Allergan, Inc; 2009.
6. Osborne DW, inventor; QLT USA, Inc., assignee. Protectant for UV-induced skin damage. United States patent 7, 399, 462, 2008 July 15.
7. Walters KA, Brain KR. How dermal absorption estimates are used in risk assessment. JE Riviere, ed. Dermal Absorption Models in Toxicology and Pharmacology. Boca Raton, FL: CRC Press; 2006: pp. 135-57.
8. Roberts MB. Nothing is Without Poison. Hong Kong: The Chinese University Press; 2002: pp. 33.
9. Kaminester LH, Pariser RJ, Pariser DM et al. A double-blind, placebo-controlled study of topical tetracaine in the treatment of herpes labialis. J Am Acad Dermatol 1999; 41: 996-1001.
10. Osborne DW, inventor; ViroTex Corporation, assignee. Composition and methods for topical application of therapeutic agents. United States patent 5, 863, 560, 1996 September 11.
11. Osborne DW, inventor; ViroTex Corporation, assignee. Composition and methods for topical application of therapeutic agents. United States patent 6, 060, 085, 2000 May 9.
12. Prow TW, Grice JE, Lin LL et al. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev 2011; 63: 470-91.
13. Bonina FP, Montenegro L. Effects of some non-toxic penetration enhancers on in vitro heparin skin permeation from gel vehicles. Int J Pharm 1994; 111: 191-6.
14. Puglia C, Bonina F, Trapani G et al. Evaluation of in vitro percutaneous absorption of lorazepam and clonazepam from hydro-alcoholic gel formulations. Int J Pharm 2001; 228: 79-87.
15. Godwin DA, Kim NH, Felton LA. Influence of Transcutol CG on the skin accumulation and transdermal permeation of ultraviolet absorbers. Eur J Pharm Biopharm 2002; 53: 23-7.
16. Otto A, Wiechers JW, Kelly CL et al. Effect of penetration modifiers on the dermal and transdermal delivery of drugs and cosmetic active ingredients. Skin Pharmacol Physiol 2008; 21: 326-34.
17. Panchagnula R, Ritschel WA. Development and evaluation of an intracutaneous depot formulation of corticosteroids using transcutol as a cosolvent: in vitro, ex vivo and in vivo rat studies. J Pharm Pharmacol 1991; 43: 609-14.
18. Thong HY, Zhai H, Maibach HI. Percutaneous penetration enhancers: an overview. Skin Pharmacol Physiol 2007; 20: 272-82.
19. Javadzadeh Y, Hamishehkar H. Enhancing percutaneous delivery of methotrexate using different types of surfactants. Colloids Surf B Biointerfaces 2011; 82: 422-6.
20. Liu H, Li S, Wang Y et al. Effect of vehicles and enhancers on the topical delivery of cyclosporine A. Int J Pharm 2006; 311: 182-6.
21. Draelos ZD, Carter E, Moloney JM et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% (Aczone) for the treatment of acne vulgaris. J Am Acad Dermatol 2007; 56: 439. e1-439.e10.
22. Differn 0.1% Cream [package insert]. Fort Worth, TX: Galderma Laboratories, L.P.; 2004.
23. Differn 0.3% Gel [package insert]. Fort Worth, TX: Galderma Laboratories, L.P.; 2007.
24. Ziana [package insert]. Scottsdale, AZ: Medicis; 2009.
25. Benzaclin [package insert]. Bridgewater, NJ: Dermik Laboratories; 2010.
26. Clindagel [package insert]. Fort Worth, TX: Galderma Laboratories, L.P.; 2007.
27. Inactive Ingredient Search for Approved Drug Products. Available at: [Accessed on July 13, 2011].
28. Sutton SVW, Porter D. Development of the antimicrobial effectiveness test as USP Chapter <51>. PDA J Pharm Sci Technol 2002; 6: 300-11.
29. Godowski KC, Dunham J, Osborne DW. Anti-P. acnes activity of proguanil. Poster presented at: American Society for Microbiology General Meeting; May 21-24, 2011; New Orleans, LA.
30. Osborne DW, Hatzenbuhler DA. The influence of skin surface lipids on topical formulations. DW Osborne, AH Amann, eds. Topical Drug Delivery Formulations. New York, NY: Marcel Dekker, Inc.; 1990: pp. 69-86.